Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Molecular Pathogenesis of Cervical Cancer (Second Edition)
share announcement

Special Issue "Molecular Pathogenesis of Cervical Cancer (Second Edition)"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 6676

Special Issue Editor

Dr. Thilo Dörk

E-Mail Website
Guest Editor
Gynecology Research Unit, Hannover Medical School, D-30625 Hannover, Germany
Interests: gynecological oncology; human molecular genetics; DNA repair
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cervical cancer is a common malignancy in women and is still a major life-threatening disease. The mechanisms of tumor development include infection with human papillomavirus and progression through distinct stages of dysplasia. Each of these steps is characterized by molecular changes and likely influenced by a balance between predisposing and protective factors as well as virus–host interactions. Furthermore, the genomic background of both the host cell and the virus may shape the risk for and development of cervical cancer. Further understanding of the molecular mechanisms governing cervical cancer development/progression is vital to develop new therapeutic strategies to improve patient treatment and survival.

Considering the importance of the topic, we have decided to launch a second edition. This Special Issue of Cancers therefore invites new research articles and timely reviews on the molecular pathogenesis of cervical cancer.

Dr. Thilo Dörk
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cervical cancer
  • cervical dysplasia
  • papillomavirus
  • hpv infection
  • cancer progression
  • cervical intraepithelial neoplasia
  • genomics
  • transcriptomics
  • epigenetics
  • genetic susceptibility
  • cancer therapy
  • cancer prevention

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

24 pages, 4897 KiB  
Article
Synergistic Combination of Luteolin and Asiatic Acid on Cervical Cancer In Vitro and In Vivo
by
Ya-Hui Chen
,
Jyun-Xue Wu
,
Shun-Fa Yang
and
Yi-Hsuan Hsiao
Cancers 2023, 15(2), 548; https://doi.org/10.3390/cancers15020548 - 16 Jan 2023
Cited by 1 | Viewed by 1947
Abstract
Cervical cancer is an important issue globally because it is the second most common gynecological malignant tumor and conventional treatment effects have been shown to be limited. Lut and AsA are plant-derived natural flavonoid and triterpenoid products that have exhibited anticancer activities and [...] Read more.
Cervical cancer is an important issue globally because it is the second most common gynecological malignant tumor and conventional treatment effects have been shown to be limited. Lut and AsA are plant-derived natural flavonoid and triterpenoid products that have exhibited anticancer activities and can modulate various signaling pathways. Thus, the aim of the present study was to evaluate whether Lut combined with AsA could enhance the anticancer effect to inhibit cervical cancer cell proliferation and examine the underlying molecular mechanisms in vitro and in vivo. The results of a CCK-8 assay showed that Lut combined with AsA more effectively inhibited the proliferation of CaSki and HeLa cells than Lut or AsA treatment alone. Lut combined with AsA caused apoptosis induction and sub-G1-phase arrest in CaSki and HeLa cells, as confirmed by flow cytometry, mitoROS analysis, antioxidant activity measurement and western blot assay. In addition, Lut combined with AsA significantly inhibited the cell migration ability of CaSki and HeLa cells in a wound-healing assay. Furthermore, Lut combined with AsA induced apoptosis and inhibited migration through downregulated PI3K/AKT (PI3K, AKT and p70S6K), JNK/p38 MAPK and FAK (integrin β1, paxillin and FAK) signaling and upregulated ERK signaling. In an in vivo study, Lut combined with AsA markedly inhibited cervical cancer cell-derived xenograft tumor growth. Collectively, the present study showed that Lut combined with AsA may be used as an anticancer agent to improve the prognosis of cervical cancer. Indeed, with additional research to develop standardized dosages, Lut and AsA combination therapy could also be applied in clinical medicine. Full article
(This article belongs to the Special Issue Molecular Pathogenesis of Cervical Cancer (Second Edition))
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

27 pages, 1887 KiB  
Review
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
by
Daniel G. Sausen
,
Oren Shechter
,
Elisa S. Gallo
,
Harel Dahari
and
Ronen Borenstein
Cancers 2023, 15(14), 3692; https://doi.org/10.3390/cancers15143692 - 20 Jul 2023
Cited by 1 | Viewed by 2911
Abstract
There is a significant body of research examining the role of human papillomavirus (HPV) in the pathogenesis of cervical cancer, with a particular emphasis on the oncogenic proteins E5, E6, and E7. What is less well explored, however, is the relationship between cervical [...] Read more.
There is a significant body of research examining the role of human papillomavirus (HPV) in the pathogenesis of cervical cancer, with a particular emphasis on the oncogenic proteins E5, E6, and E7. What is less well explored, however, is the relationship between cervical cancer and herpes simplex virus (HSV). To date, studies examining the role of HSV in cervical cancer pathogenesis have yielded mixed results. While several experiments have determined that HPV/HSV-2 coinfection results in a higher risk of developing cervical cancer, others have questioned the validity of this association. However, clarifying the potential role of HSV in the pathogenesis of cervical cancer may have significant implications for both the prevention and treatment of this disease. Should this relationship be clarified, treating and preventing HSV could open another avenue with which to prevent cervical cancer. The importance of this is highlighted by the fact that, despite the creation of an effective vaccine against HPV, cervical cancer still impacts 604,000 women and is responsible for 342,000 deaths annually. This review provides an overview of HSV and HPV infections and then delves into the possible links between HPV, HSV, and cervical cancer. It concludes with a summary of preventive measures against and recent treatment advances in cervical cancer. Full article
(This article belongs to the Special Issue Molecular Pathogenesis of Cervical Cancer (Second Edition))
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

21 pages, 1241 KiB  
Perspective
Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer
by
Robert Polten
,
Ivana Kutle
,
Jens Hachenberg
,
Rüdiger Klapdor
,
Michael Morgan
and
Axel Schambach
Cancers 2023, 15(1), 263; https://doi.org/10.3390/cancers15010263 - 30 Dec 2022
Viewed by 1457
Abstract
Cervical cancer is one of the most common malignancies in women, and the majority of cases are caused by infection with high-risk human papilloma virus (HPV) subtypes. Despite effective preventative measures, such as vaccinations against HPV, over 300,000 women die world-wide from cervical [...] Read more.
Cervical cancer is one of the most common malignancies in women, and the majority of cases are caused by infection with high-risk human papilloma virus (HPV) subtypes. Despite effective preventative measures, such as vaccinations against HPV, over 300,000 women die world-wide from cervical cancer each year. Once cervical cancer is diagnosed, treatment may consist of radial hysterectomy, or chemotherapy and radiotherapy, or a combination of therapies dependent upon the disease stage. Unfortunately, overall prognosis for patients with metastatic or recurrent disease remains poor. In these cases, immunotherapies may be useful based on promising preclinical work, some of which has been successfully translated to the clinic. For example, approaches using monoclonal antibodies directed against surface proteins important for control of immune checkpoints (i.e., immune checkpoint inhibitors) were shown to improve outcome in many cancer settings, including cervical cancer. Additionally, initial clinical studies showed that application of cytotoxic immune cells modified to express chimeric antigen receptors (CAR) or T cell receptors (TCR) for better recognition and elimination of tumor cells may be useful to control cervical cancer. This review explores these important topics, including strengths and limitations of standard and developing approaches, and how some novel treatment strategies may be optimally used to offer the best possible treatment for cervical cancer patients. Full article
(This article belongs to the Special Issue Molecular Pathogenesis of Cervical Cancer (Second Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop